glp-1 for diabetes type 2 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read The ABC's of GLP-1s: Benefits,

Individual outcomes in laboratory settings may vary and are not guaranteed

The potential advent of an effective tau-directed disease-targeted therapies (DTTs) for AD may increase the volume of patients presenting earlier in the disease continuum, and increase complexity in workflow, infrastructure, treatment decision-making, treatment administration and monitoring, and patient tracking

cagrilintide does it via the amylin receptor (AMY1R/AMY3R heterodimers) in the area postrema

The UK's Leading Dihexa Resource Evidence-based information on Dihexa (PNB-0408)

TRIUMPH-4 has already delivered positive topline results

B12/MIC is most effective when used as part of a healthy lifestyle, including a balanced diet & regular exercise